[Protective properties of candidate genetically engineered vaccines against avian influenza viruses constructed on the basis of recombinant adenoviral vectors]
- PMID: 20734718
[Protective properties of candidate genetically engineered vaccines against avian influenza viruses constructed on the basis of recombinant adenoviral vectors]
Abstract
Aim: To design and study the properties of candidate vaccines against avian influenza based on recombinant adenoviral vectors expressing H5 hemagglutinin.
Materials and methods: Recombinant adenoviral vectors were constructed as described in "Stratagene" (Ad Easy Adenoviral Vector System). For immunization of animals, recombinant candidate vaccines were administered intranasally twice. Titer of hemagglutinating antibodies were measured by hemaglutination inhibition assay.
Results: It was demonstrated that administration of vaccines to animals completely protects them from a lethal dose challenge with H5N2 influenza virus. Protective effect of vaccines remained for 6 months after immunization. Additionally, highly effective cross-protection of the immunized animals against heterologous strain of H5 influenza virus was demonstrated.
Conclusion: Obtained results show good prospects for usage of recombinant adenoviral vectors as a basis for development of new generation effective vaccines against influenza.
Similar articles
-
Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.Vaccine. 2017 Nov 1;35(46):6345-6353. doi: 10.1016/j.vaccine.2017.04.042. Epub 2017 Apr 26. Vaccine. 2017. PMID: 28456525
-
Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.Antiviral Res. 2017 Nov;147:29-36. doi: 10.1016/j.antiviral.2017.09.009. Epub 2017 Sep 20. Antiviral Res. 2017. PMID: 28941982
-
Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.J Virol. 2017 Feb 28;91(6):e01693-16. doi: 10.1128/JVI.01693-16. Print 2017 Mar 15. J Virol. 2017. PMID: 28077631 Free PMC article.
-
[Tetravaccine--new fundamental approach to prevention of influenza pandemic].Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Zh Mikrobiol Epidemiol Immunobiol. 2007. PMID: 17882832 Review. Russian.
-
Development and use of fowlpox vectored vaccines for avian influenza.Ann N Y Acad Sci. 2006 Oct;1081:193-201. doi: 10.1196/annals.1373.023. Ann N Y Acad Sci. 2006. PMID: 17135511 Review.
Cited by
-
Recombinant influenza vaccines.Acta Naturae. 2012 Oct;4(4):17-27. Acta Naturae. 2012. PMID: 23346377 Free PMC article.
-
Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts.PLoS One. 2018 Jan 29;13(1):e0191574. doi: 10.1371/journal.pone.0191574. eCollection 2018. PLoS One. 2018. PMID: 29377916 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical